A review of premature frailty in HIV-infected persons; another manifestation of HIV-related accelerated aging

Current Aging Science

Volumn 4, Issue 1, 2011, Pages 33-41

  Önen, Nur F ^a   Overton, E Turner ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Accelerated aging; Frailty; Hiv infection

Indexed keywords

ALBUMIN;

AGING; ATHEROGENESIS; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CHRONIC KIDNEY DISEASE; COMORBIDITY; EXERCISE; FRAIL ELDERLY; HOSPITALIZATION; HOST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; HYPOALBUMINEMIA; IMMUNE DEFICIENCY; IMMUNE DYSREGULATION; IMMUNE RESPONSE; INFLAMMATION; MALE HOMOSEXUAL; MEDLINE; MORTALITY; PATHOGENESIS; PEER REVIEW; PREVALENCE; PRIORITY JOURNAL; REVIEW; SOCIOECONOMICS; T CELL DEPLETION; VIREMIA; VIRUS REPLICATION; YOGA; PATHOPHYSIOLOGY; PREMATURE AGING;

AGING, PREMATURE; COMORBIDITY; HIV INFECTIONS; HUMANS; PREVALENCE;

EID: 79958830246     PISSN: 18746098     EISSN: 18746128     Source Type: Journal    
DOI: 10.2174/1874609811104010033     Document Type: Review

References (121)

1. El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355 (22): 2283-96.
2. Appay V, Almeida JR, Sauce D, Autran B, Papagno L. Accelerated immune senescence and HIV-1 infection. Exp Gerontol 2007; 42 (5): 432-7.
3. Deeks SG. Immune dysfunction, inflammation, and accelerated aging in patients on antiretroviral therapy. Top HIV Med 2009; 17 (4): 118-23.
4. Martínez E, Larrousse M, Gatell JM. Cardiovascular disease and HIV infection: host, virus, or drugs? Curr Opin Infect Dis 2009; 22 (1): 28-34.
5. Mondy KE. Determinants of endothelial function in human immunodeficiency virus infection: a complex interplay among therapy, disease, and host factors. J Cardiometab Syndr 2008; 3 (2): 88-92.
6. Fine DM, Atta MG. Kidney disease in the HIV-infected patient. AIDS Patient Care STDS 2007; 21 (11): 813-24.
7. Amorosa V, Tebas P. Bone disease and HIV infection. Clin Infect Dis 2006; 42 (1): 108-14.
8. Clifford DB. HIV-associated neurocognitive disease continues in the antiretroviral era. Top HIV Med 2008; 16 (2): 94-8.
9. Anuurad E, Semrad A, Berglund L. Human immunodeficiency virus and highly active antiretroviral therapy-associated metabolic disorders and risk factors for cardiovascular disease. Metab Syndr Relat Disord 2009; 7 (5): 401-10.
10. Clifford GM, Polesel J, Rickenbach M, Dal Maso L, Keiser O, Kofler A, et al. Swiss HIV Cohort. Cancer risk in the Swiss HIV cohort study: Associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 2005; 97 (6): 425-32.
11. Spano JP, Costagliola D, Katlama C, Mounier N, Oksenhendler E, Khayat D. AIDS-related malignancies: state of the art and therapeutic challenges. J Clin Oncol 2008; 26 (29): 4834-442.
12. Patel P, Hanson DL, Sullivan PS, Novak RM, Moorman AC, Tong TC, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med 2008; 148 (10): 728-36.
13. Önen NF, Agbebi A, Shacham E, Stamm KE, Önen AR, Overton ET. Frailty among HIV-infected persons in an urban outpatient care setting. J Infect 2009; 59 (5): 346-52.
14. Desquilbet L, Jacobson LP, Fried LP, Phair JP, Jamieson BD, Holloway M, et al. HIV-1 infection is associated with an earlier occurrence of a phenotype related to frailty. J Gerontol 2007; 62: 1279-86.
15. Terzian AS, Holman S, Nathwani N, Robison E, Weber K, Young M, et al. Women's Interagency HIV Study. Factors associated with preclinical disability and frailty among HIV-infected and HIVuninfected women in the era of cART. J Womens Health 2009; 18 (12): 1965-74.
16. Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D; Clinical Epidemiology Group from the French Hospital Database. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003; 17 (17): 2479-86.
17. Friis-Møller N, Sabin CA, Weber R, d'Arminio Monforte A, El- Sadr WM, Reiss P, et al. Combination antiretroviral therapy and risk of myocardial infarction. N Engl J Med 2003; 349: 1993-2003.
18. Lenhard JM, Croom DK, Weiel JE, Winegar DA. HIV protease inhibitors stimulate hepatic triglyceride synthesis. Arterioscler Thromb Vasc Biol 2000; 20 (12): 2625-9.
19. Caron M, Auclair M, Vissian A, Vigouroux C, Capeau J. Contribution of mitochondrial dysfunction and oxidative stress to cellular premature senescence induced by antiretroviral thymidine analogues. Antivir Ther 2008; 13 (1): 27-38.
20. Jericó C, Knobel H, Calvo N, Sorli ML, Guelar A, Gimeno-Bayón JL, et al. Subclinical carotid atherosclerosis in HIV-infected patients: role of combination antiretroviral therapy. Stroke 2006; 37 (3): 812-7.
21. Seaberg EC, Muñoz A, Lu M, Detels R, Margolick JB, Riddler SA, et al. Multicenter AIDS Cohort Study.Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003. AIDS 2005; 19 (9): 953-60.
22. Stein JH, Klein MA, Bellehumeur JL, McBride PE, Wiebe DA, Otvos JD, et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001; 104 (3): 257-62.
23. Marra CM, Zhao Y, Clifford DB, Letendre S, Evans S, Henry K, et al. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 2009; 23 (11): 1359-66.
24. Schweinsburg BC, Taylor MJ, Alhassoon OM, Gonzalez R, Brown GG, Ellis RJ, et al. HNRC Group. Brain mitochondrial injury in human immunodeficiency virus-seropositive (HIV+) individuals taking nucleoside reverse transcriptase inhibitors. J Neurovirol 2005; 11 (4): 356-64.
25. Overton ET, Nurutdinova D, Freeman J, Seyfried W, Mondy KE. Factors associated with renal dysfunction within an urban HIVinfected cohort in the era of highly active antiretroviral therapy. HIV Med 2009; 10 (6): 343-50.
26. Önen NF, Overton ET, Seyfried W, Stumm ER, Snell M, Mondy K, et al. Effects of HIV and highly active antiretroviral therapy in an aging outpatient population. HIV Clin Trials 2010; 11(2): 100-9.
27. Lichtenstein KA. Redefining lipodystrophy syndrome: risks and impact on clinical decision making. J Acquir Immune Defic Syndr 2005; 39: 395-400.
28. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005; 352 (1): 48-62.
29. Wohl D, Scherzer R, Heymsfield S, Simberkoff M, Sidney S, Bacchetti P, et al; FRAM Study Investigators. The associations of regional adipose tissue with lipid and lipoprotein levels in HIVinfected men. J Acquir Immune Defic Syndr 2008; 48 (1): 44-52.
30. Mondy K, Yarasheski K, Powderly WG, Whyte M, Claxton S, DeMarco D, et al. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis 2003; 36 (4): 482-90.
31. Amorosa V, Synnestvedt M, Gross R, Friedman H, MacGregor RR, Gudonis D, et al. A tale of 2 epidemics: the intersection between obesity and HIV infection in Philadelphia. J Acquir Immune Defic Syndr 2005; 39 (5): 557-61.
32. Mondy K, Overton ET, Grubb J, Tong S, Seyfried W, Powderly W, et al. Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population. Clin Infect Dis 2007; 44 (5): 726-734.
33. U.S. Department of Health and Human Services Center for Disease Control and Prevention. Preventing Heart Disease and Stroke: Addressing the Nation's Leading Killers 2005. Atlanta: Centers for Disease Control and Prevention 2005.
34. Currier JS, Kendall MA, Zackin R, Henry WK, Alston-Smith B, Torriani FJ, et al; AACTG 5078 Study Team. Carotid artery intima-media thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure. AIDS 2005; 19: 927-933.
35. Currier JS, Taylor A, Boyd F, Dezii CM, Kawabata H, Burtcel B, et al. Coronary heart disease in HIV-infected individuals. JAIDS 2003; 33: 506-12.
36. Fausto A, Bongiovanni M, Cicconi P, Menicagli L, Ligabò EV, Melzi S, et al. Potential predictive factors of osteoporosis in HIVpositive subjects. Bone 2006; 38: 893-97.
37. Grulich AE, Li Y, McDonald A, Correll PK, Law MG, Kaldor JM. Rates of non-AIDS-defining cancers in people with HIV infection before and after AIDS diagnosis. AIDS 2002; 16 (8): 1155-61.
38. Silverberg MJ, Neuhaus J, Bower M, Gey D, Hatzakis A, Henry K, et al. Risk of cancers during interrupted antiretroviral therapy in the SMART study. AIDS 2007; 21 (14): 1957-63.
39. Herida M, Mary-Krause M, Kaphan R, Cadranel J, Poizot-Martin I, Rabaud C, et al. Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. Clin Oncol 2003; 21 (18): 3447-53.
40. Palella FJ Jr, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, et al; HIV Outpatient Study Investigators. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43 (1): 27-34.
41. Appay V, Sauce D. Immune activation and inflammation in HIV-1 infection: causes and consequences. J Pathol 2008; 214(2): 231-241.
42. De Martinis M, Franceschi C, Monti D, Ginaldi L. Inflammation markers predicting frailty and mortality in the elderly. Exp Mol Pathol 2006; 80: 219-27.
43. Paiardini M, Frank I, Pandrea I, Apetrei C, Silvestri G. Mucosal immune dysfunction in AIDS pathogenesis. AIDS Rev 2008; 10 (1): 36-46.
44. Douek DC, Roederer M, Koup RA. Emerging concepts in the immunopathogenesis of AIDS. Annu Rev Med 2009; 60: 471-84.
45. Schneider T, Jahn HU, Schmidt W, Riecken EO, Zeitz M, Ullrich R. Loss of CD4 T lymphocytes in patients infected with human immunodeficiency virus type 1 is more pronounced in the duodenal mucosa than in the peripheral blood. Berlin Diarrhea/Wasting Syndrome Study Group. Gut 1995; 37 (4): 524-9.
46. Guadalupe M, Reay E, Sankaran S, Prindiville T, Flamm J, McNeil A, et al. Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. J Virol 2003; 77 (21): 11708-17.
47. Griffiths PD. CMV as a cofactor enhancing progression of AIDS. J Clin Virol 2006; 35: 489-92.
48. Anton PA, Mitsuyasu RT, Deeks SG, Scadden DT, Wagner B, Huang C, et al. Multiple measures of HIV burden in blood and tissue are correlated with each other but not with clinical parameters in aviremic subjects. AIDS 2003; 17 (1): 53-63.
49. Poles MA, Boscardin WJ, Elliott J, Taing P, Fuerst MM, McGowan I, et al. Lack of decay of HIV-1 in gut-associated lymphoid tissue reservoirs in maximally suppressed individuals. J Acquir Immune Defic Syndr 2006; 43 (1): 65-8.
50. Aldrovandi GM, Feuer G, Gao L, Jamieson B, Kristeva M, Chen IS, et al. The SCID-hu mouse as a model for HIV-1 infection. Nature 1993; 363: 732-6.
51. Schacker TW, Brenchley JM, Beilman GJ, Reilly C, Pambuccian SE, Taylor J, et al. Lymphatic tissue fibrosis is associated with redcued numbers of naïve CD4+ T cells in human immunodeficiency virus type 1 infection. Clin Vaccine Immunol 2006; 13: 556-60.
52. Effros RB, Fletcher CV, Gebo K, Halter JB, Hazzard WR, McFarland Horne F, et al. Workshop on HIV infection and aging. What is known and future research directions. CID 2008; 47: 542-53.
53. van Leuven SI, Franssen R, Kastelein JJ, Levi M, Stroes ES, Tak PP. Systemic inflammation as a risk factor for atherothrombosis. Rheumatology (Oxford) 2008; 47 (1): 3-7.
54. Hazleton JE, Berman JW, Eugenin EA. Novel mechanisms of CNS damage in HIV infection. HIV/AIDS - Res Palliative Care 2010; 2: 39-49.
55. Tebas P, Henry WK, Matining R, Weng-Cherng D, Schmitz J, Valdez H, et al. Metabolic and immune activation effects of treatment interruption in chronic HIV-1 infection: implications for cardiovascular risk. PLoS One 2008; 3 (4): e2021.
56. Herrera MD, Mingorance C, Rodriguez-Rodriguez R, Alvarez de Sotomayor M. Endothelial dysfunction and aging: an update. Aging Res Rev 2010; 9(2): 142-52.
57. Clarkson P, Celermajer DS, Powe AJ, Donald AE, Henry RM, Deanfield JE. Endothelium-dependent dilatation is impaired in young healthy subjects with a family history of premature coronary disease. Circulation 1997; 96: 3378-83.
58. Balletshofer BM, Rittig K, Enderle MD, Volk A, Maerker E, Jacob S, et al. Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance. Circulation 2000; 101: 1780-4.
59. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000; 101: 948-54.
60. Green DA, Masliah E, Vinters HV, Beizai P, Moore DJ, Achim CL. Brain deposition of beta-amyloid is a common pathologic feature in HIV positive patients. AIDS 2005; 19 (4): 407-11.
61. De Ronchi D, Faranca I, Berardi D, Scudellari P, Borderi M, Manfredi R, et al. Risk factors for cognitive impairment in HIV-1infected persons with different risk behaviors. Arch Neurol 2002; 59 (5): 812-8.
62. Stout JC, Ellis RJ, Jernigan TL, Archibald SL, Abramson I, Wolfson T, et al. Progressive cerebral volume loss in human immunodeficiency virus infection: a longitudinal volumetric magnetic resonance imaging study. Arch Neurol 1998; 55: 161-8.
63. Guaraldi G, Zona S, Alexopoulos N, Orlando G, Carli F, Ligabue G, et al. Coronary aging in HIV-infected patients. Clin Infect Dis 2009; 49 (11): 1756-62.
64. Kline ER, Sutliff RL. The roles of HIV-1 proteins and antiretroviral drug therapy in HIV-1-associated endothelial dysfunction. J Investig Med 2008; 56 (5): 752-69.
65. Chi D, Henry J, Kelley J, Thorpe R, Smith JK, Krishnaswamy G. The effects of HIV infection on endothelial function. Endothelium 2000; 7 (4): 223-42.
66. Paladugu R, Fu W, Conklin BS, Lin PH, Lumsden AB, Yao Q, et al. HIV Tat protein causes endothelial dysfunction in porcine coronary arteries. J Vasc Surg 2003; 38 (3): 549-55.
67. Barbaro G. Vascular injury, hypertension and coronary artery disease in human immunodeficiency virus infection. Clin Ter 2008; 159 (1): 51-5.
68. Pontrelli G, Martino AM, Tchidjou HK, Citton R, Mora N, Ravà L, et al. HIV is associated with thrombophilia and high D-dimer in children and adolescents. AIDS 2010; 24(8): 1145-51.
69. Solages A, Vita JA, Thornton DJ, Murray J, Heeren T, Craven DE, et al. Endothelial function in HIV-infected persons. Clin Infect Dis 2006; 42 (9): 1325-32.
70. van Wijk JP, de Koning EJ, Cabezas MC, Joven J, op't Roodt J, Rabelink TJ, et al. Functional and structural markers of atherosclerosis in human immunodeficiency virus-infected patients. J Am Coll Cardiol 2006; 47 (6): 1117-23.
71. Ances BM, Sisti D, Vaida F, Liang CL, Leontiev O, Perthen JE, et al. Resting cerebral blood flow: a potential biomarker of the effects of HIV in the brain. Neurology 2009; 73 (9): 702-8.
72. Torriani FJ, Komarow L, Parker RA, Cotter BR, Currier JS, Dubé MP, et al. Endothelial function in human immunodeficiency virusinfected antiretroviral-naïve subjects before and after starting potent antiretroviral therapy. J Am Coll Cardiol 2008; 52: 569-76.
73. Lang P-O, Michel J-P, Zekry D. Frailty syndrome: A transitional state in a dynamic process. Gerontology 2009; 55: 539-49.
74. Fried LP, Xue QL, Cappola AR, Ferrucci L, Chaves P, Varadhan R, et al. Nonlinear multisystem physiological dysregulation associated with frailty in older women: implications for etiology and treatment. J Gerontol A Biol Sci Med Sci 2009; 64 (10): 1049-57.
75. Ahmed N, Mandel R, Fain MJ. Frailty: an emerging geriatric syndrome. Am J Med 2007; 120: 748-53.
76. Gill TM, Gahbauer EA, Allore HG, Han L. Transitions between frailty states among community-living older persons. Arch Intern Med. 2006; 166: 418-23.
77. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001; 56a: M146-M56.
78. Desquiblet L, Margolick JB, Fried LP, Phair JP, Jamieson BD, Holloway M, et al; for the Multicenter AIDS Cohort Study. Relationship between a frailty-related phenotype and progressive deterioration of the immune system in HIV-infected men. J Acquir Immune Defic Syndr 2009; 50 (3): 299-306.
79. Woods NF, LaCroix AZ, Gray SL, Aragaki A, Cochrane BB, Brunner RL, et al. Frailty: emergence and consequences in women aged 65 and older in the Women's Health Initiative Observational Study. J Am Geriatr Soc 2005; 53: 1321-30.
80. Hirsch C, Anderson ML, Newman A, Kop W, Jackson S, Gottdiener J, et al. The association of race with frailty: the cardiovascular health study. Ann Epidemiol 2006; 16: 545-53.
81. Espinoza SE, Hazuda HP. Frailty in older Mexican-American and European American adults. Is there an ethnic disparity? J Am Geriatr Soc 2008; 56 (9): 1744-9.
82. Walston J, McBurnie MA, Newman A, Tracy RP, Kop WJ, Hirsch CH, et al. Frailty and activation of the inflammation and coagulation systems with and without clinical morbidities: Results from the Cardiovascular Health Study. Arch Intern Med 2002; 162: 2333-41.
83. Semba RD, Bartali B, Zhou J, Blaum C, Ko CW, Fried LP. Low serum micronutrient concentrations predict frailty among older women living in the community. J Gerontol 2006; 61A: 594-9.
84. Avila-Funes JA, Amieva H, Barberger-Gateau P, Le Goff M, Raoux N, Ritchie K, et al. Cognitive impairment improves the predictive validity of the phenotype of frailty for adverse health outcomes: the three-city study. J Am Geriatr Soc 2009; 57 (3): 453-61.
85. Markle-Reid M, Browne G. Conceptualizations of frailty in relation to older adults. J Adv Nurs 2003; 44: 58-68.
86. Rothman MD, Leo-Summers L, Gill TM. Prognostic significance of potential frailty criteria. JAGS 2008; 56: 2211-6.
87. Avila-Funes JA, Helmer C, Amieva H, Barberger-Gateau P, Le Goff M, Ritchie K, et al. Frailty among community-dwelling elderly people in France: the three-city study. J Gerontol A Biol Sci Med Sci 2008; 63 (10): 1089-96.
88. Wilhelm-Leen ER, Hall YN, K Tamura M, Chertow GM. Frailty and chronic kidney disease: the Third National Health and Nutrition Evaluation Survey. Am J Med 2009; 122 (7): 664-71.e2.
89. Waltson J, Fried LP. Frailty and the older man. Med Clin North Am 1999; 83: 1173-94.
90. Puts MTE, Lips P, Deeg DJ. Sex differences in the risk of frailty for mortality independent of disability and chronic diseases. J Am Geriatr Soc 2005; 53: 40-7.
91. Ottenbacher KJ, Ostir GV, Peek MK, Snih SA, Raji MA, Markides KS. Frailty in older Mexican Americans. J Am Geriatr Soc 2005; 53: 1524-31.
92. Joseph C, Kenny AM, Taxel P, Lorenzo JA, Duque G, Kuchel GA. Role of endocrine-immune dysregulation in osteoporosis, sarcopenia, frailty and fracture risk. Mol Aspects Med 2005; 26: 181-201.
93. Lunney JR, Lynn J, Foley DJ, Lipson S, Guralnik JM. Patterns of functional decline at the end of life. JAMA 2003; 289: 2387-92.
94. Walston J, Hadley EC, Ferrucci L, Guralnik JM, Newman AB, Studenski SA, et al. Research agenda for frailty in older adults: toward a better understanding of physiology and etiology: summary from the American Geriatrics Society/National Institute on Aging Research Conference on Frailty in Older Adults. J Am Geriatr Soc 2006; 54 (6): 991-1001.
95. Lee DH, Buth KJ, Martin BJ, Yip AM, Hirsch GM. Frail Patients Are at Increased Risk for Mortality and Prolonged Institutional Care After Cardiac Surgery. Circulation 2010 Feb 16. [Epub ahead of print].
96. Fried LP, Ferrucci L, Darer J, Williamson JD, Anderson G. Untangling the concepts of disability, frailty and co-morbidity: implications for improved targeting and care. J Gerontol Biol Sci Med Sci 1999; 48: 445-69.
97. Önen NF, Shacham E, Stamm KE, Turner Overton E. Sexual behaviors and results of bacterial sexually transmitted infections testing among frail HIV-infected individuals. J Int Assoc Phys AIDS Care (Chic Ill) 2010; 9 (1): 30-3.
98. Giunta S. Exploring the complex relations between inflammation and aging (inflamm-aging): anti-inflamm-aging remodeling of inflammaging, from robustness to frailty. Inflamm Res 2008; 57: 558-63.
99. Carvalhaes-Neto N, Huayllas MK, Ramos LR, Cendoroglo MS, Kater CE. Cortisol, DHEAS and aging: resistance to cortisol suppression in frail institutionalized elderly. J Endocrinol Invest 2003; 26 (1): 17-22.
100. Herold MJ, McPherson KG, Reichardt HM. Glucocorticoids in T cell apoptosis and function. Cell Mol Life Sci 2006; 63 (1): 60-72.
101. Bjelaković G, Stojanovic I, Jevtovic-Stoimenov T, Pavlović D, Kocić G, Kamenov B, et al. Thymus as a target tissue of glucocorticoid action: what are the consequences of glucocorticoids thymectomy? J Basic Clin Physiol Pharmacol 2009; 20 (2): 99-125.
102. De Fanis U, Wang GC, Fedarko NS, Walston JD, Casolaro V, Leng SX. T-lymphocytes expressing CC chemokine receptor-5 are increased in frail older adults. J Am Geriatr Soc 2008; 56 (5): 904-8.
103. Leng SX, Cappola AR, Andersen RE, Blackman MR, Koenig K, Blair M, et al. Serum levels of insulin-like growth factor-I (IGF-I) and dehydroepiandrosterone sulfate (DHEA-S), and their relationships with serum interleukin-6, in the geriatric syndrome of frailty. Aging Clin Exp Res 2004; 16 (2): 153-7.
104. Puts MT, Visser M, Twisk JW, Deeg DJ, Lips P. Endocrine and inflammatory markers as predictors of frailty. Clin Endocrinol 2005; 63: 403-41.
105. Kanapuru B, Ershler WB. Inflammation, coagulation, and the pathway to frailty. Am J Med 2009; 122 (7): 605-13.
106. Topinkova E. Aging, disability and frailty. Ann Nutr Metab 2008; 52 (Suppl 1): 6-11.
107. Zapanti E, Terzidis K, Chrousos G. Dysfunction of the hypothalamic- pituitary-adrenal axis in HIV infection and disease. Hormones (Athens) 2008; 7 (3): 205-16.
108. Drain PK, Kupka R, Mugusi F, Fawzi WW. Micronutrients in HIVpositive persons receiving highly active antiretroviral therapy. Am J Clin Nutr 2007; 85 (2): 333-45.
109. LaCroix A, Gray S, Aragaki A, Cochrane BB, Newman AB, Kooperberg CL, et al. Statin use and incident frailty in women aged 65 years or older: Prospective findings from the Women's Health Initiative Observational Study. J Gerontol 2008; 63A (4): 369-75.
110. Di Bari M, van de Poll-Franse LV, Onder G, Kritchevsky SB, Newman A, Harris TB, et al. Antihypertensive medications and differences in muscle mass in older persons: The Health, Aging and Body Composition Study. J Am Geriatr Soc 2004; 52: 961-6.
111. Onder G, Penninx BW, Balkrishnan R, Fried LP, Chaves PH, Williamson J, et al. Relation between use of angiotensin-converting enzyme inhibitors and muscle strength and physical function in older women: an observational study. Lancet 2002; 359(9310): 926-30.
112. Binder EF, Schechtman KB, Ehsani AA, Steger-May K, Brown M, Sinacore DR, et al. Effects of exercise training on frailty in community-dwelling older adults: results of a randomized, controlled trial. J Am Geriatr Soc 2002; 50 (12): 1921-8.
113. Fiatarone MA, O'Neill EF, Ryan ND, Clements KM, Solares GR, Nelson ME, et al. Exercise training and nutritional supplementation for physical frailty in very elderly people. N Engl J Med 1994; 330(25): 1769-75.
114. Cade WT, Reeds DN, Mondy KE, Overton ET, Grassino J, Tucker S, et al. Yoga lifestyle intervention reduces blood pressure in HIVinfected adults with cardiovascular disease risk factors. HIV Med 2010; 11 (6): 379-88.
115. Mutimura E, Crowther NJ, Stewart A, Cade WT. The human immunodeficiency virus and the cardiometabolic syndrome in the developing world: an African perspective. J Cardiometab Syndr 2008; 3(2): 106-10.
116. Donnell D, Baeten JD, Kiarie J, Thomas KK, Stevens W, Cohen CR, et al, for the Partners in Prevention HSV/HIV Transmission Study Team. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 2010; 375: 2092-8.
117. Branson Handsfield HH, Lampe MA, Janssen RS, Taylor AW, Lyss SB, Clark JE; Centers for Disease Control and Prevention (CDC). Revised recommendations for HIV testing of adults, adolescents and pregnant women in health-care settings. MMWR Recomm Rep 2006; 55 (RR-14): 1-17.
118. Shacham E, Nurutdinova D, Satyanarayana V, Stamm K, Overton ET. Routine screening for depression: identifying a challenge for successful HIV care. AIDS Patient Care STDS 2009; 23 (11): 949-955.
119. Kacank D, Jacobson DL, Spiegelman D, Wanke C, Isaac R, Wilson IB. Incident depression symptoms are associated with poorer HAART adherence: a longitudinal analysis from the Nutrition for Healthy Living study. J Acquir Immune Defic Syndr 2010; 53 (2): 266-72.
120. Ettenhofer ML, Hinkin CH, Castellon SA, Durvasula R, Ullman J, Lam M, et al. Aging, neurocognition, and medication adherence in HIV infection. Am J Geriatr Psychiatry 2009; 17 (4): 281-90.
121. Pandya R, Krentz HB, Gill MJ, Power C. HIV-related neurological syndromes reduce health-related quality of life. Can J Neurol Sci 2005; 32 (2): 201-4.